Medtronic's Jason Fontana offers an update on next-generation Symplicity Spyral devices, procedures and a new feature they're ...

Analysts are optimistic about Medtronic (MDT) after the Centers for Medicare and Medicaid Services (CMS) proposed to cover ...

On Thursday, the US Centers for Medicare & Medicaid Services (CMS) issued its proposal for covering radiofrequency- or ...

Medtronic and Recor Medical both issued statements supporting new Medicare coverage for their respective renal denervation ...

About the Paradise Ultrasound Renal Denervation System The Paradise uRDN system is a first-of-its-kind ultrasound-based RDN ...

Medtronic is studying the use of its nitinol-enabled Symplicity Spyral renal denervation (RDN) catheter combined with hepatic ...

Evidence-based recommendations on alcohol-mediated perivascular renal sympathetic denervation for resistant hypertension. This involves putting alcohol into the wall of a renal artery to destroy renal ...

GALWAY, Ireland, Nov. 1, 2024 /PRNewswire/ -- Medtronic plc (NYSE: MDT), a global leader in healthcare technology, today announced that the Centers for Medicare & Medicaid Services (CMS) has granted ...

The system can accurately map the renal nerve sites to selectively denervate renal sympathetic nerves, and has a good match with the anatomical shape of the renal artery with additional flexible ...

The ultrasound renal denervation system (Paradise, Recor) lowers BP by denervating the sympathetic nerves surrounding the renal arteries, reducing the overactivity that can lead to hypertension.

Following recent FDA approval of two renal denervation systems for the treatment of hypertension, experts speculate on which patients will be prioritized for the procedure.

The Simplicity Spyral RDN system is designed to lower BP by delivering radiofrequency energy through the wall of the renal artery to denervate the kidney from sympathetic nerve hyperactivity.